Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for persistent FVPED in neovascular AMD
NCT01495208Phase 4Withdrawn
- Sponsor
- Vitreous Retina Macula Consultants of New York
- Start
- Dec 2011
- Primary completion
- Oct 2012
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in fibrovascular pigment epithelial detachment, neovascular age-related macular degeneration (NVAMD), sponsored by Vitreous Retina Macula Consultants of New York. Planned start Dec 2011; status: withdrawn.
02
Drugs
aflibercept
03
Conditions
fibrovascular pigment epithelial detachmentneovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01495208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01495208.